|
|
 Previous Article | Table of Contents | Next Article 
An In Vitro Model for Toxin-Mediated Vascular Leak Syndrome: Ricin Toxin A Chain Increases the Permeability of Human Endothelial Cell Monolayers
Alan L. Lindstrom,
Stanley L. Erlandsen,
John H. Kersey, and
Christopher A. Pennell
From the Departments of Laboratory Medicine and Pathology, Cell Biology and Neuroanatomy, the Cancer Center and the Center for Immunology, University of Minnesota, Minneapolis, MN.
Vascular leak syndrome (VLS) is the dose-limiting toxicity observed in clinical trials of immunotoxins containing ricin toxin A chain (RTA). RTA itself is thought to cause VLS by damaging vascular endothelial cells, but the exact mechanism remains unclear. This is partially due to the paucity of appropriate models. To study VLS, we developed an in vitro model in which human umbilical vein-derived endothelial cells were first grown to confluence on microporous supports and then cultured under low pressure in the presence or absence of RTA. Endothelial cell barrier function was assessed by measuring the volume of fluid that passed through each monolayer per unit time. We found that RTA significantly increased monolayer permeability at times and concentrations consistent with the onset of VLS in patients treated with RTA-based immunotoxins. Scanning electron microscopy showed that intercellular gaps formed in endothelial monolayers exposed to RTA. Intercellular gap formation followed endothelial cell death caused by the enzymatic activity of RTA. We conclude that RTA is directly toxic to endothelial cells in vitro and speculate that this contributes to VLS in vivo.
Blood, Vol. 90 No. 6 (September 15), 1997:
pp. 2323-2334
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. Wong, V. Korcheva, D. B. Jacoby, and B. E. Magun
Proinflammatory responses of human airway cells to ricin involve stress-activated protein kinases and NF-{kappa}B
Am J Physiol Lung Cell Mol Physiol,
December 1, 2007;
293(6):
L1385 - L1394.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-H. Wu, S.-F. Shih, and J.-Y. Lin
Ricin Triggers Apoptotic Morphological Changes through Caspase-3 Cleavage of BAT3
J. Biol. Chem.,
April 30, 2004;
279(18):
19264 - 19275.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Messmann, E. S. Vitetta, D. Headlee, A. M. Senderowicz, W. D. Figg, J. Schindler, D. F. Michiel, S. Creekmore, S. M. Steinberg, D. Kohler, et al.
A Phase I Study of Combination Therapy with Immunotoxins IgG-HD37-Deglycosylated Ricin A Chain (dgA) and IgG-RFB4-dgA (Combotox) in Patients with Refractory CD19(+), CD22(+) B Cell Lymphoma
Clin. Cancer Res.,
April 1, 2000;
6(4):
1302 - 1313.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M W J d. Brok, G C de Gast, J H M Schellens, and J H Beijnen
Targeted toxins
Journal of Oncology Pharmacy Practice,
December 1, 1999;
5(4):
149 - 165.
[Abstract]
[PDF]
|
|
|
|
|
